AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
BioNTech SE (ASX:BNTX)
102.25 USD
-4.150 3.900%Sponsored Reports
Loading...
| Previous Close (in USD) | 106.4 |
|---|---|
| Change | -4.150 3.900% |
| 52 W H/L (in USD) | 125.830/85.213 |
| EBITDA (in USD) | -46.9M |
| PE Ratio | 192.04 |
| Volume | 941533 |
| Diluted Eps TTM | 0.49 |
| Total Assets (in USD) | 23006.3M |
|---|---|
| Total Liabilities (in USD) | 2760.4M |
| Revenue TTM (in USD) | 2729.6M |
| Cash (in USD) | 11663.7M |
| Market Cap (in USD) | 22,677.158 M |
| Revenue Per Share TTM | 11.369 |
| Gross Profit TTM (in USD) | 16065.2M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Employees: 6133
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Prof. Ugur Sahin M.D. | Co-Founder, CEO & Chair of the Management Board | 1965 |
| 2. | Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer & Member of Management Board | 1967 |
| 3. | Prof. Christoph Hubert Huber M.D., Ph.D. | Co-Founder & Member of Supervisory Board | 1944 |
| 4. | Mr. Jens H. Holstein | CFO & Member of Management Board | 1963 |
| 5. | Dr. Sierk Poetting Ph.D. | MD, COO & Member of Management Board | 1973 |
| 6. | Mr. Ryan Richardson | Chief Strategy Officer, MD & Member of Management Board | 1979 |
| 7. | Mr. Sean Marett | Chief Bus. Officer, Chief Commercial Officer & Member of Management Board | 1965 |
| 8. | Sylke Maas Ph.D. | VP of Investor Relations and Bus. Strategy | NA |
| 9. | Dr. James Timothy Patrick Ryan Ph.D. | Sr. VP & Gen. Counsel | NA |
| 10. | Michael Boehler | MD & Head of Global External Communications | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+2.890 2.816% | 103.43 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+2.440 2.379% | 105 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+0.440 0.098% | 448.31 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-1.250 0.168% | 742.19 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Income Before Tax | 1186.1M | 12954.1M | 15046.4M | -145.802M | -179.44M |
| Minority Interest | - | - | 0M | 0M | 0.116M |
| Net Income | 930.3M | 9434.4M | 10292.5M | 15.2M | -179.172M |
| Selling General Administrative | 495M | 484.7M | 278.5M | 94.049M | 40.692M |
| Gross Profit | 3219.2M | 12778.6M | 15116M | -222.037M | -135.238M |
| Reconciled Depreciation | 183.4M | 123.3M | 75.2M | 38.744M | 33.896M |
| Ebit | 972M | 12642.7M | 15283.8M | -82.417M | -181.518M |
| Ebitda | 1155.4M | 13096.3M | 14970.7M | -42.109M | -146.167M |
| Depreciation And Amortization | 183.4M | 453.6M | -313.1M | 40.308M | 35.351M |
| Operating Income | 690.4M | 12642.7M | 15283.8M | -82.417M | -181.518M |
| Other Operating Expenses | 2914.8M | 4667.9M | 4060.8M | 564.742M | 290.107M |
| Interest Expense | 7.738M | 18.9M | 5.4M | 64.949M | 1.718M |
| Tax Provision | 255.8M | 3519.7M | 4753.9M | -161M | -0.268M |
| Interest Income | 357.6M | 330.3M | 1.5M | 1.564M | 1.781M |
| Net Interest Income | 349.7M | 311.4M | -25.8M | -3.487M | -0.263M |
| Income Tax Expense | 255.8M | 3519.7M | 4753.9M | -161M | -0.268M |
| Total Revenue | 3819M | 17310.6M | 18976.7M | 482.325M | 108.589M |
| Total Operating Expenses | 2315M | 135.9M | 200.1M | -139.62M | 46.28M |
| Cost Of Revenue | 599.8M | 4532M | 3860.7M | 704.362M | 243.827M |
| Total Other Income Expense Net | -67.8M | 311.4M | -237.4M | -63.385M | 2.078M |
| Net Income From Continuing Ops | 930.3M | 9434.4M | 10292.5M | 15.198M | -179.172M |
| Net Income Applicable To Common Shares | - | - | 10292.5M | 15.198M | -179.056M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 23006.3M | 23279.1M | 15830.8M | 2318.62M | 797.647M |
| Intangible Assets | 804.1M | 158.5M | 144.6M | 109.793M | 86.456M |
| Other Current Assets | 280.9M | 271.9M | 64.9M | 60.966M | 1.182M |
| Total Liab | 2760.4M | 3223.5M | 3937.1M | 946.774M | 304.155M |
| Total Stockholder Equity | 20245.9M | 20055.6M | 11893.7M | 1371.846M | 493.492M |
| Other Current Liab | 1335.1M | 2633.4M | 3002.6M | 103.05M | 16.439M |
| Common Stock | 248.6M | 248.6M | 246.3M | 246.31M | 232.304M |
| Capital Stock | 248.6M | 248.6M | 246.3M | 246.31M | 232.304M |
| Retained Earnings | 19763.3M | 18833M | 9882.9M | -409.629M | -424.827M |
| Good Will | 362.5M | 61.2M | 57.8M | 53.697M | 2.978M |
| Other Assets | - | 249.2M | 22.2M | 168.231M | 2.403M |
| Cash | 11663.7M | 13875.1M | 1692.7M | 1210.209M | 519.149M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 2070.5M | 2950.6M | 3481.6M | 606.014M | 138.142M |
| Current Deferred Revenue | 353.3M | 77.1M | 189.1M | 391.534M | 93.583M |
| Net Debt | -11444.6M | -13662.9M | -1391.2M | -970.02M | -450.245M |
| Short Term Debt | 28.1M | 36M | 129.9M | 9.142M | 7.622M |
| Short Long Term Debt | 28.1M | 36M | 129.9M | 9.142M | 0M |
| Short Long Term Debt Total | 219.1M | 212.2M | 301.5M | 240.189M | 68.904M |
| Other Stockholder Equity | 1218.6M | -5.3M | -3.8M | 1509.662M | -5.525M |
| Property Plant Equipment | - | - | 520.4M | 325.956M | 148.062M |
| Total Current Assets | 19527.3M | 21922M | 15072.3M | 1666.896M | 560.151M |
| Long Term Investments | 1176.1M | 80.2M | 21.3M | - | 0M |
| Short Term Investments | 4885.3M | 189.4M | 381.6M | 137.234M | 1.68M |
| Net Receivables | 2339.7M | 7146M | 12382.1M | 166.366M | 20.205M |
| Long Term Debt | 191M | 176.2M | 171.6M | 231.047M | 68.904M |
| Inventory | 357.7M | 439.6M | 502.5M | 64.12M | 11.722M |
| Accounts Payable | 354M | 204.1M | 160M | 102.288M | 20.498M |
| Accumulated Other Comprehensive Income | -984.6M | 979.3M | 1768.3M | 25.503M | 691.54M |
| Non Currrent Assets Other | 83.4M | 6.5M | 0.8M | 1.045M | 0.002M |
| Non Current Assets Total | 3479M | 1357.1M | 758.5M | 651.724M | 237.496M |
| Capital Lease Obligations | - | - | - | - | 0M |
| Long Term Debt Total | - | - | - | - | 68.904M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | -6954.5M | -35.3M | -566.1M | -144.848M | -77.115M |
| Total Cashflows From Investing Activities | - | - | -566.1M | -144.848M | -77.115M |
| Total Cash From Financing Activities | -778.6M | -1419.3M | 94.2M | 894.725M | 383.29M |
| Net Income | 1186.1M | 12954.1M | 15046.4M | -145.802M | -179.44M |
| Change In Cash | -2211.4M | 12182.4M | 482.5M | 691.06M | 107.654M |
| Begin Period Cash Flow | 13875.1M | 1692.7M | 1210.2M | 519.149M | 411.495M |
| End Period Cash Flow | 11663.7M | 13875.1M | 1692.7M | 1210.209M | 519.149M |
| Total Cash From Operating Activities | 5371.4M | 13577.4M | 889.7M | -13.474M | -198.537M |
| Depreciation | 183.4M | 123.3M | 75.2M | 38.744M | 33.896M |
| Other Cashflows From Investing Activities | - | - | - | - | -6.035M |
| Dividends Paid | 0M | 484.3M | 0M | 0M | 0M |
| Change To Inventory | 81.9M | 62.9M | -438.4M | -49.794M | -5.798M |
| Sale Purchase Of Stock | -738.5M | -986.4M | 0M | 0M | 375.351M |
| Other Cashflows From Financing Activities | 0.3M | 0.8M | -566.1M | 156.027M | 11M |
| Capital Expenditures | 705.5M | 363.3M | 154M | 85.446M | 71.08M |
| Change In Working Capital | 5574.8M | 4518.5M | -10730.4M | -93.097M | -83.436M |
| Other Non Cash Items | -1275.5M | -4127.1M | 212.5M | 114.475M | 0.262M |
| Free Cash Flow | 4665.9M | 13214.1M | 735.7M | -98.92M | -269.617M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Performer (AFRIS) | 8 months ago | 30261592 |
| 2. | Vanguard Capital Opportunity Inv | 7 months ago | 2357016 |
| 3. | AF High Growth (AFRIS) | 8 months ago | 2299505 |
| 4. | FvS SICAV Multiple Opportunities F | 9 months ago | 2120112 |
| 5. | Harding Loevner International Eq Instl | 7 months ago | 1855233 |
| 6. | iShares Biotechnology ETF | 6 months ago | 1532557 |
| 7. | PRIMECAP Odyssey Aggressive Growth | 7 months ago | 1362792 |
| 8. | Global Balanced (AFRIS) | 8 months ago | 1054891 |
| 9. | FvS Multiple Opportunities II I | 9 months ago | 1027264 |
| 10. | American Funds New Perspective A | 7 months ago | 799519 |
| 11. | Capital Group New Perspective Comp | 7 months ago | 799519 |
| 12. | Baillie Gifford WW L/T Glb Gr B USD Acc | 7 months ago | 650357 |
| 13. | PRIMECAP Odyssey Growth | 7 months ago | 437900 |
| 14. | Baillie Gifford L/T Glb Gr Invm B Acc | 7 months ago | 428986 |
| 15. | First Trust NYSE Arca Biotech ETF | 6 months ago | 426947 |
| 16. | Fidelity Contrafund | 7 months ago | 342586 |
| 17. | Harding Loevner International Equity K | 7 months ago | 341665 |
| 18. | Deka-GlobalChampions CF | 11 months ago | 340000 |
| 19. | AF Global Equity (AFRIS) | 8 months ago | 301666 |
| 20. | ACATIS Datini Valueflex Fonds A | 7 months ago | 280000 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Baillie Gifford & Co Limited. | 7 months ago | 8358939 |
| 2. | PRIMECAP Management Company | 7 months ago | 4807918 |
| 3. | Temasek Holdings Ltd. | 10 months ago | 4518080 |
| 4. | Harding Loevner L.P. | 10 months ago | 3944474 |
| 5. | Flossbach von Storch AG | 7 months ago | 3468986 |
| 6. | BlackRock Inc | 10 months ago | 1640016 |
| 7. | Capital World Investors | 7 months ago | 943116 |
| 8. | Altrinsic Global Advisors LLC | 7 months ago | 712708 |
| 9. | Quinn Opportunity Partners LLC | 10 months ago | 674583 |
| 10. | Morgan Stanley - Brokerage Accounts | 10 months ago | 628251 |
| 11. | Deutsche Bank AG | 10 months ago | 536853 |
| 12. | First Trust Advisors L.P. | 10 months ago | 416891 |
| 13. | DekaBank Deutsche Girozentrale | 7 months ago | 411897 |
| 14. | Goldman Sachs Group Inc | 10 months ago | 365756 |
| 15. | ClearBridge Advisors, LLC | 7 months ago | 361813 |
| 16. | Gilder Gagnon Howe & CO LLC | 10 months ago | 359708 |
| 17. | Squarepoint Ops LLC | 10 months ago | 316299 |
| 18. | Amundi | 10 months ago | 247016 |
| 19. | BAMCO Inc | 10 months ago | 242348 |
| 20. | Mitsubishi UFJ Trust & Banking Corp | 7 months ago | 216950 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
